Skip to main content
BioCardia, Inc. logo

BioCardia, Inc. — Investor Relations & Filings

Ticker · BCDA ISIN · US09060U5074 LEI · 5493003EDBXRQRW22O75 US Manufacturing
Open in API
Filings indexed 1,023 across all filing types
Latest filing 2019-11-06 Legal Proceedings Report
Country US United States of America
Listing US BCDA

About BioCardia, Inc.

https://www.biocardia.com/

BioCardia, Inc. is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's lead program is the CardiAMP® cell therapy system, an autologous therapy that uses a patient's own bone marrow cells to potentially stimulate the body's natural healing response in the heart. This therapy is primarily being evaluated for the treatment of ischemic heart failure. In addition to its autologous platform, BioCardia is also developing CardiALLO™, an allogeneic cell therapy platform using cells from qualified donors. The company's approach integrates biotherapeutic candidates with proprietary delivery systems for targeted administration.

Recent filings

Filing Released Lang Actions
FORM 8-K
Legal Proceedings Report Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The content describes a legal dispute involving patent rights, arbitration, and litigation between BioCardia and other parties. It details the filing of a counterclaim and ongoing legal proceedings. There are no financial statements, earnings data, or management discussion of financial results. The document is primarily an update on legal proceedings and related corporate events. Therefore, it fits best under the category of Legal Proceedings Report (LTR). The document length (5327 characters) and detailed narrative support this classification rather than a brief announcement or other report type.
2019-11-06 English
SC 13D/A
Major Shareholding Notification
2019-10-23 English
FORM 4
Director's Dealing
2019-10-21 English
SCHEDULE 13G
Major Shareholding Notification
2019-10-18 English
FORM DEFA14A
Remuneration Information Classification · 95% confidence The document is titled 'FORM DEFA14A' and is identified as a 'Definitive Additional Materials' filing related to a proxy statement under Schedule 14A pursuant to Section 14(a) of the Securities Exchange Act of 1934. The form DEFA14A is specifically used for additional definitive proxy solicitation materials, which are related to remuneration and compensation disclosures or other proxy-related information. Given the form type and the context, this document fits the category of Remuneration Information filings, which detail compensation for top executives and directors. The document length is short and it is a filing form, not a full report or presentation. Therefore, the correct classification is DEF 14A with high confidence.
2019-10-15 English
FORM DEF 14A
Proxy Solicitation & Information Statement
2019-10-15 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.